Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, Young June | - |
dc.contributor.author | Yi, Seonju | - |
dc.contributor.author | Hwang, Insob | - |
dc.contributor.author | Kim, Jia | - |
dc.contributor.author | Park, Young-Joon | - |
dc.contributor.author | Cho, Eunhee | - |
dc.contributor.author | Jo, Myoungyoun | - |
dc.contributor.author | Lee, Hyunju | - |
dc.contributor.author | Choi, Eun Hwa | - |
dc.date.accessioned | 2022-03-02T15:42:23Z | - |
dc.date.available | 2022-03-02T15:42:23Z | - |
dc.date.created | 2022-03-02 | - |
dc.date.issued | 2022-01-31 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137519 | - |
dc.description.abstract | In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10th-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19. (c) 2021 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choe, Young June | - |
dc.identifier.doi | 10.1016/j.vaccine.2021.12.044 | - |
dc.identifier.scopusid | 2-s2.0-85122615229 | - |
dc.identifier.wosid | 000747074400001 | - |
dc.identifier.bibliographicCitation | VACCINE, v.40, no.5, pp.691 - 694 | - |
dc.relation.isPartOf | VACCINE | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 40 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 691 | - |
dc.citation.endPage | 694 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordAuthor | Coronavirus disease 2019 | - |
dc.subject.keywordAuthor | Covid-19 | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | Vaccine | - |
dc.subject.keywordAuthor | Vaccination | - |
dc.subject.keywordAuthor | Adolescent | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.